683 related articles for article (PubMed ID: 27411022)
1. Multiple myeloma: patient outcomes in real-world practice.
Yong K; Delforge M; Driessen C; Fink L; Flinois A; Gonzalez-McQuire S; Safaei R; Karlin L; Mateos MV; Raab MS; Schoen P; Cavo M
Br J Haematol; 2016 Oct; 175(2):252-264. PubMed ID: 27411022
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma: practice patterns across Europe.
Raab MS; Cavo M; Delforge M; Driessen C; Fink L; Flinois A; Gonzalez-McQuire S; Safaei R; Karlin L; Mateos MV; Schoen P; Yong K
Br J Haematol; 2016 Oct; 175(1):66-76. PubMed ID: 27291397
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.
Mohty M; Knauf W; Romanus D; Corman S; Verleger K; Kwon Y; Cherepanov D; Cambron-Mellott MJ; Vikis HG; Gonzalez F; Gavini F; Ramasamy K
Eur J Haematol; 2020 Sep; 105(3):308-325. PubMed ID: 32418256
[TBL] [Abstract][Full Text] [Related]
4. Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.
Mohty M; Cavo M; Fink L; Gonzalez-McQuire S; Leleu H; Mateos MV; Raab MS; Schoen P; Yong K
Eur J Haematol; 2019 Aug; 103(2):107-115. PubMed ID: 31112311
[TBL] [Abstract][Full Text] [Related]
5. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma.
Bruno AS; Willson JL; Opalinska JM; Nelson JJ; Lunacsek OE; Stafkey-Mailey DR; Willey JP
Expert Rev Hematol; 2020 Sep; 13(9):1017-1025. PubMed ID: 32844683
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Gonzalez-McQuire S; Yong K; Leleu H; Mennini FS; Flinois A; Gazzola C; Schoen P; Campioni M; DeCosta L; Fink L
J Med Econ; 2018 May; 21(5):450-467. PubMed ID: 29278014
[TBL] [Abstract][Full Text] [Related]
7. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
[TBL] [Abstract][Full Text] [Related]
9. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Djebbari F; Sharpley FA; McLain-Smith S; Vallance G; Eyre TA; Kothari J; Moore S; Ramasamy K
PLoS One; 2020; 15(2):e0229469. PubMed ID: 32084254
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients.
Rampotas A; Djebbari F; Panitsas F; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Lim WY; Eyre TA; Moore S; Ramasamy K; Kothari J
Eur J Haematol; 2021 Apr; 106(4):563-573. PubMed ID: 33496996
[TBL] [Abstract][Full Text] [Related]
11. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.
Jagannath S; Roy A; Kish J; Lunacsek O; Globe D; Eaddy M; Kuriakose ET; Willey J; Butler-Bird S; Siegel D
Expert Rev Hematol; 2016 Jul; 9(7):707-17. PubMed ID: 27291638
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain.
Lehne M; Kortüm KM; Ramasamy K; Zamagni E; d'Estrubé T; Zhuleku E; Hanna M; Shukla S; Ghiani M; Maywald U; Wilke T; Kellermann L; Perera S
Eur J Haematol; 2024 May; 112(5):701-713. PubMed ID: 38146208
[TBL] [Abstract][Full Text] [Related]
13. Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review.
Mateos MV; Fink L; Koneswaran N; Intorcia M; Giannopoulou C; Niepel D; Cavo M
BMC Cancer; 2020 Mar; 20(1):170. PubMed ID: 32126974
[TBL] [Abstract][Full Text] [Related]
14. Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study.
Dhanasiri S; Hollier-Hann G; Stothard C; Dhanda DS; Davies FE; Rodriguez-Otero P
Clin Ther; 2021 Nov; 43(11):1983-1996.e3. PubMed ID: 34736769
[TBL] [Abstract][Full Text] [Related]
15. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.
Blimark CH; Turesson I; Genell A; Ahlberg L; Björkstrand B; Carlson K; Forsberg K; Juliusson G; Linder O; Mellqvist UH; Nahi H; Kristinsson SY;
Haematologica; 2018 Mar; 103(3):506-513. PubMed ID: 29217784
[TBL] [Abstract][Full Text] [Related]
16. Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe.
Zhang J; Kelkar SS; Prabhu VS; Qiao Y; Grall V; Miles N; Marth C
BMJ Open; 2024 Apr; 14(4):e079447. PubMed ID: 38569701
[TBL] [Abstract][Full Text] [Related]
17. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
[TBL] [Abstract][Full Text] [Related]
18. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K; Wellard C; Moore E; McQuilten Z; Blacklock H; Harrison SJ; Ho PJ; King T; Quach H; Mollee P; Walker P; Wood E; Spencer A;
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e510-e520. PubMed ID: 33785297
[TBL] [Abstract][Full Text] [Related]
19. Management of Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany.
Steinmetz HT; Singh M; Milce J; Haidar M; Rieth A; Lebioda A; Kohnke J
Adv Ther; 2022 Mar; 39(3):1247-1266. PubMed ID: 35034310
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study.
Ocio EM; Montes-Gaisán C; Bustamante G; Garzón S; González E; Pérez E; Sirvent M; Arguiñano JM; González Y; Ríos R; de Miguel D; Grande M; Fernández A; Naves A; Rosiñol L
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):e241-e249. PubMed ID: 34774462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
